



Daily *Derivatives*

04 March, 2026

DERIVATIVES

Key Indices

Index	Close	Changes (%)
NIFTY	24865.70	-1.24
SENSEX	80238.85	-1.29
BANKNIFTY	59839.65	-1.14
INDIA VIX	17.13	25.01

Market Outlook

Nifty witnessed a significant gap-down opening, tracking weakness in global markets amid escalating geopolitical tensions. The index retested its recent February low near the 24,600 mark before staging a mild relief rally and eventually settling at 24,865. On the technical front, the index has decisively broken below its 200-DEMA, which is now expected to act as an immediate resistance zone for the near term. From a derivatives perspective, the upcoming weekly expiry data shows fresh call writing at the 25,000 strike, positioning it as a near-term hurdle. As Nifty failed to reclaim this level, further fresh call writing will intensify and it may once again retest the 24,600–24,500 support zone.



TRADE IDEA OF THE DAY -
SUNPHARMA

**BUY 30 MAR 1750 CALL
SELL 30 MAR 1800 CALL**

Entry Range	20 - 22
Target Range	40
Stop Loss	10



Rationale

- On the daily chart SUNPHARMA has witnessed a robust recovery from its key moving average of 50-DEMAs. In addition to this a recent crossover suggests that the short-term trend has turned decisively upward.
- On the technical front prices are forming a clear higher-low pattern, supported by a rising trendline, indicating strong buying interest on every minor dip.
- The 14-Day RSI is holding steady around 60 mark, signalling a healthy momentum with plenty of "room to run" before reaching overbought territory.
- The MACD indicator shows a bullish convergence, with the signal line trending upward and the histogram continued to trade in a bullish trajectory, confirming a positive bias for the coming sessions.


NIFTY

Nifty	24988.00
OI (In Lots)	234987
CHANGE IN OI (%)	7.18
PRICE CHANGE (%)	-1.38


BANKNIFTY

Nifty	60255.00
OI (In Lots)	63977
CHANGE IN OI (%)	30.34
PRICE CHANGE (%)	-1.06

NIFTY OI



BANKNIFTY OI



FII's Activity Index Futures



FII's Long Short Ratio



Long Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
TIINDIA	2764.3	1.39	16115	19.24
SIEMENS	3433.1	2.35	14599	11.48
HCLTECH	1379.7	0.28	80053	11.10
OIL	487.4	2.34	12235	7.99

Short Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
ABCAPITAL	341.5	-4.38	27675	36.89
LTF	278.25	-7.27	28635	31.87
JUBLFOOD	511.45	-0.21	22828	18.93
BSE	2711.6	-3.21	27339	18.81

Breakout Stocks (1 Month High)

Name	LTP	% Change	22 DAY HIGH
TIINDIA	2831.9	2.68	2768.9
KEI	5107.5	2.05	5048.8
-	-	-	-
-	-	-	-

Breakdown Stocks (1 Month Low)

Name	LTP	% Change	22 DAY LOW
SUZLON	41.2	-3.96	42.62
NBCC	89.91	-3.28	92.51
IREDA	115.87	-3.01	118.47
INOXWIND	90.1	-2.51	91.93

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
ADANIANT	2156	2189	2124.6	2082	2041
ADANIPTS	1501	1533	1470.3	1434	1398
APOLLOHOSP	7864	7949	7791.5	7650	7521
ASIANPAINT	2333	2363	2307.1	2278	2254
AXISBANK	1383	1400	1372.3	1352	1337
BAJAJ-AUTO	9941	10130	9776	9565	9377
BAJAJFINSV	1974	2014	1941.9	1911	1888
BAJFINANCE	987	1000	978.25	965	955
BEL	460	466	453.95	445	436
BHARTIARTL	1896	1920	1873.2	1848	1824
CIPLA	1366	1381	1351.6	1325	1298
COALINDIA	431	437	426.25	418	410
DRREDDY	1318	1349	1294.4	1240	1191
EICHERMOT	7965	8121	7826	7684	7559
ETERNAL	246	250	242.87	236	231
GRASIM	2806	2841	2777.3	2716	2661
HCLTECH	1388	1405	1371	1352	1333
HDFCBANK	890	897	879.4	873	864
HDFCLIFE	718	727	707.3	701	693
HINDALCO	959	977	940	909	878
HINDUNILVR	2351	2384	2320.6	2287	2257
ICICIBANK	1384	1394	1374	1360	1345
INDIGO	4632	4731	4520.4	4467	4401
INFY	1300	1313	1288.9	1275	1261
ITC	318	321	314.9	309	304

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
JIOFIN	253	257	249	244	240
JSWSTEEL	1277	1288	1267.3	1250	1234
KOTAKBANK	415	418	413.1	407	403
LT	4138	4223	4066.7	3972	3891
M&M	3370	3418	3334.3	3278	3234
MARUTI	14633	14899	14388	14153	13939
MAXHEALTH	1093	1107	1083.6	1061	1043
NESTLEIND	1290	1302	1279.7	1263	1249
NTPC	382	387	377.55	368	359
ONGC	290	299	282.2	275	269
POWERGRID	300	304	296.8	291	285
RELIANCE	1379	1397	1358	1341	1323
SBILIFE	2058	2084	2032.2	2001	1970
SBIN	1198	1207	1189.9	1180	1171
SHRIRAMFIN	1067	1085	1052.5	1034	1019
SUNPHARMA	1773	1790	1752.5	1725	1694
TATACONSUM	1143	1162	1125.2	1108	1092
TATASTEEL	215	220	211.01	206	200
TCS	2630	2649	2613.5	2587	2562
TECHM	1364	1384	1345.4	1324	1303
TITAN	4329	4398	4270.3	4192	4124
TMPV	381	391	370.6	358	346
TRENT	3895	3958	3848.5	3763	3693
ULTRACEMCO	12640	12779	12521	12343	12185
WIPRO	201	204	198.57	195	192

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

Our Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

S.No.	Statement	Answer	
		Tick Appropriate	
		Yes	No
1.	I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)		No
2.	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance?		No
3.	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?		
4.	I/we have received any compensation from the subject company in the past twelve months?		No
5.	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
6.	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
7.	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
8.	I/we have served as an officer, director or employee of the subject company?		No
9.	I/we have been engaged in market making activity for the subject company?		No

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

Copyright: This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.